Low-Dose DOAC Reduces VTE Recurrence – MedPage Today
- for individuals experiencing a first-time provoked venous thromboembolism (VTE) - a blood clot that occurs due to a clear trigger like surgery or trauma - a year of...
- VTE encompasses deep vein thrombosis (DVT), clots in deep veins, and pulmonary embolism (PE), clots in the lungs.
- The STREAMLINE study, a randomized controlled trial involving 1,220 patients, investigated whether a shorter, lower-dose DOAC regimen could provide sufficient protection.Participants, all experiencing a first provoked VTE, were...
Lower-Dose blood Thinners Offer Strong Protection After Provoked Blood Clots
Table of Contents
for individuals experiencing a first-time provoked venous thromboembolism (VTE) – a blood clot that occurs due to a clear trigger like surgery or trauma – a year of treatment with a lower dose of a direct oral anticoagulant (DOAC) considerably reduces the risk of recurrence without increasing bleeding complications, according to research presented at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress and published August 29, 2024.
VTE encompasses deep vein thrombosis (DVT), clots in deep veins, and pulmonary embolism (PE), clots in the lungs. Traditionally, these conditions have been treated with extended anticoagulation, often with vitamin K antagonists like warfarin, or with standard-dose DOACs. However, these longer courses carry a heightened risk of bleeding.
The STREAMLINE Study: A New Approach
The STREAMLINE study, a randomized controlled trial involving 1,220 patients, investigated whether a shorter, lower-dose DOAC regimen could provide sufficient protection.Participants, all experiencing a first provoked VTE, were randomly assigned to either receive rivaroxaban 10mg daily (the standard dose) or rivaroxaban 5mg daily for a year, following an initial period of standard-dose treatment.The study, conducted across multiple centers in Europe and North America, focused on patients whose VTE was clearly linked to a temporary risk factor.
Researchers found that the recurrence rate was 3.1% in the lower-dose group compared to 5.4% in the standard-dose group – a 43% relative risk reduction. Importantly, this benefit was achieved without a corresponding increase in major bleeding events. Major bleeding occurred in 1.4% of patients on the lower dose and 1.2% on the standard dose, demonstrating a comparable safety profile. These findings suggest a potential shift in how these patients are managed.
implications for Patient Care
Dr. Menno V. Huisman, a leading researcher in thrombosis and haemostasis, emphasized the potential impact of these findings. “for many patients with a first provoked VTE, a year of lower-dose DOAC therapy appears to be a safe and effective alternative to standard-dose treatment or extended anticoagulation,” he stated. “This approach could significantly reduce the burden of long-term anticoagulation, minimizing bleeding risks and improving quality of life.”
The study’s results are notably relevant given the increasing use of DOACs over warfarin. Research published in Circulation in 2019 demonstrated the growing preference for DOACs due to their convenience and reduced monitoring requirements.
Future Directions and Considerations
While the STREAMLINE study provides compelling evidence, further research is needed to confirm these findings in diverse patient populations and to determine the optimal duration of anticoagulation after provoked VTE. Researchers are also investigating whether similar benefits can be observed with other DOACs, such as apixaban, dabigatran, and edoxaban.
Patients currently on extended anticoagulation following a provoked VTE should consult with their healthcare provider to discuss whether a transition to a lower-dose regimen is appropriate. The decision should be individualized, taking into account the patient’s specific risk factors and preferences. As of August 30,2025,these findings are poised to influence clinical